Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study.
Sonomoto K, Nakayamada S, Fujino Y, Miyata H, Kubo S, Fujita Y, Inoue Y, Matsunaga S, Iwata S, Hanami K, Todoroki Y, Yoshinari-Korekoda H, Kawabe A, Yamaguchi A, Ueno M, Satoh-Kanda Y, Kanda R, Funada M, Ohkubo N, Kusaka K, Kosaka S, Nagayasu A, Fukuyo S, Nawata M, Miyazaki Y, Tokunaga M, Tanaka K, Okada Y, Tanaka Y.
Sonomoto K, et al.
Rheumatology (Oxford). 2024 Aug 1;63(8):2239-2248. doi: 10.1093/rheumatology/kead579.
Rheumatology (Oxford). 2024.
PMID: 37934120
Patients not receiving anti-osteoporotic agents (anti-OP) at baseline with no history of fracture experienced a significant decrease in both femoral neck (F: mean 0.666-0.655 g/cm3) and radial (R: 0.518-0.514) BMD at week 26. Despite maintaining low CDAI levels during week …
Patients not receiving anti-osteoporotic agents (anti-OP) at baseline with no history of fracture experienced a significant decrease in both …